medigraphic.com
ISSN 1029-3043 (Electronic)

2013, Number 4

<< Back Next >>

Medicentro 2013; 17 (4)

Minimal hepatic encephalopathy. Clinical implications, diagnosis and management

Padilla RMA, Fernández AME

Language: Spanish
References: 42
Page: 143-150
PDF size: 117.14 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Montgomery JY, Bajaj JS. Advances in the Evaluation and Management of Minimal Hepatic Encephalopathy. Curr Gastroenterol Rep. 2011:13:26-33.

  2. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50:2014-21.

  3. Sharma P, Sharma BC, Puri V, Sarin SK. Minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction. Am J Gastroenterol. 2008; 103:1406-12.

  4. Sharma P, Sharma BC, Puri V, Sarin SK. Natural history of minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction. Am J Gastroenterol. 2009;104:885-90.

  5. Dhiman RK, Saraswat VA, Sharma BK, Sarin SK, Chawla YK, Butterworth R, et al. Indian National Association for Study of the Liver: Minimal hepatic encephalopathy: Consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol. 2010;25:1029-41.

  6. Sharma P. Minimal hepatic encephalopathy. J Assoc Physicians India. 2009;57: 760–3.

  7. Radha K, Dhiman RK, Chawla YK. Minimal hepatic encephalopathy. Indian J Gastroenterol. 2009 Jan.-Feb.;28:5-16.

  8. Sharma P, Sharma BC. Predictors of minimal hepatic encephalopathy in patients with cirrhosis. Saudi J Gastroenterol. 2010;16:181-7.

  9. Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol. 2008;14:3609-15.

  10. Aguilar J, Serrano P. Tratamiento de las enfermedades hepáticas y biliares. [CD-ROOM]. España: Asociación española para estudio del hígado; 2007.

  11. Zhou YQ, Chen SY, Jiang LD. Development and evaluation of the quality of life instrument in chronic liver disease patients with minimal hepatic encephalopathy. J Gastroenterol Hepatol. 2009;24:408-15.

  12. Kim Y, Park G, Lee M, Lee JH. Impairment of driving ability and neuropsychological function in patients with MHE disease. Cyberpsychol Behav. 2009;12:433-6.

  13. Bajaj JS, Hafeezullah M, Zadvornova Y. The effect of fatigue on driving skills in patients with hepatic encephalopathy. Am J Gastroenterol. 2009;104:898-905.

  14. Bajaj JS, Saeian K, Schubert CM. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009;50:1175-83.

  15. Kircheis G, Knoche A, Hilger N. Hepatic encephalopathy and fitness to drive. Gastroenterology. 2009;137:1706-15.

  16. Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol. 2007;102:1903-9.

  17. Weissenborn K, Heidenreich S, Giewekemeyer K, Ruckert N, Hecker H. Memory function in early hepatic encephalopathy. J Hepatol. 2003;39:320-5.

  18. Bajaj JS, Saeian K, Christensen KM. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol. 2008;103:1707-15.

  19. Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2008;20:506-11.

  20. Mittal VV, Sharma P, Sharma BC, Sarin S. Treatment of minimal hepatic encephalopathy: A randomised controlled trial comparing lactulose, probiotics and l-ornithine l-aspartate with placebo. Hepatology. 2009;50(Suppl.):4-7.

  21. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137:885-91.

  22. Dhiman RK, Kurmi R, Thumburu KK. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci 2010;55:2381-90.

  23. Bajaj JS, Hafeezullah M, Franco J. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology. 2008;135:1591-600.

  24. Stewart CA, Enders FT, Schneider N. Development of a three-factor neuropsychological approach for detecting minimal hepatic encephalopathy Liver Int. 2010;30:841–9.

  25. Ferenci P, Lockwood A, Mullen K. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716-21.

  26. Amodio P, Wenin H, Del Piccolo F, Mapelli D, Montagnese S, Pellegrini A, et al. Variability of trail making test, symbol digit test and line trait test in normal people. A normative study taking into account age-dependent decline and sociobiological variables. Aging Clin Exp Res. 2002;14:117-31.

  27. Randolph C, Hilsabeck R, Kato A. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009;29:629–35.

  28. Dhiman RK, Kurmi R, Thumburu KK. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci. De próxima aparición 2010.

  29. Weissenborn K. PHES: one label, different goods? J Hepatol. 2008;49:308-12.

  30. Amodio P, Campagna F, Olianas S. Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. J Hepatol. 2008;49:346–53.

  31. Sharma P, Sharma BC, Sarin SK. Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis. Hepatobiliary Pancreat Dis Int. 2010;9:27-32.

  32. Amodio P, Ridola L, Schiff S. Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology. 2010;139:510-8.

  33. Singhal A, Nagarajan R, Hinkin CH. Two-dimensional MR spectroscopy of minimal hepatic encephalopathy and neuropsychological correlates in vivo. J Magn Reson Imaging. 2010;32:35- 43.

  34. Holecek M. Three targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition. 2010;26:482-90.

  35. Abdo-Francis J, Perez-Hernandez J, Hinojosa-Ruiz A, Hernandez-Vasquez J. Use of Lornithine L-aspartate (LOLA) reduces time of hospital stay in patients with hepatic encephalopathy [in Spanish]. Rev Gastroenterol Mex. 2010; 75:135-41.

  36. Schmid M, Peck-Radosavljevic M, Konig F. A doubleblind, randomized, placebo-controlled trial of intravenous Lornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int. 2010;30:574-82.

  37. Bass NM, Mullen KD, Sanyal A. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010 Jun. 25;362:1071-81.

  38. Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol. 2010;16:3347-57.

  39. Bajaj JS. The modern management of hepatic encephalopathy [review article]. Aliment Pharmacol Ther. 2010;31:537-47.

  40. McGuire BM, Zupanets IA, Lowe ME. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology. 2010; 51:2077-85.

  41. Sidhu S, Goyal O, Mishra BP. Rifaximin improves cognitive functions and health-related quality of life in patients with minimal hepatic encephalopathy: a prospective, randomized, double-blind, placebo-controlled trial (the RIME Trial) [abstract]. Gastroenterology. 2010;139:e18-e19.

  42. Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2010 Sep. 21;140(2):[aprox. 10 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020996/




2020     |     www.medigraphic.com